Wisteria sinensis (Sims) Sweet Wisteria floribunda (Willd) DC
1. NAME |
1.1 Scientific name |
1.2 Family |
1.3 Common name(s) |
2. SUMMARY |
2.1 Main risks and target organs |
2.2 Summary of clinical effects |
2.3 Diagnosis |
2.4 First-aid measures and management principles |
2.5 Poisonous parts |
2.6 Main toxins |
3. CHARACTERISTICS |
3.1 Description of the plant |
3.1.1 Special identification features |
3.1.2 Habitat |
3.1.3 Distribution |
3.2 Poisonous parts of the plant |
3.3 The toxin(s) |
3.3.1 Name(s) |
3.3.2 Description, chemical structure, stability |
3.3.3 Other physico-chemical characteristics |
3.4 Other chemical contents of the plant |
4. USES/CIRCUMSTANCES OF POISONING |
4.1 Uses |
4.1.1 Uses |
4.1.2 Description |
4.2 High risk circumstances |
4.3 High risk geographical areas |
5. ROUTES OF ENTRY |
5.1 Oral |
5.2 Inhalation |
5.3 Dermal |
5.4 Eye |
5.5 Parenteral |
5.6 Others |
6. KINETICS |
6.1 Absorption by route of exposure |
6.2 Distribution by route of exposure |
6.3 Biological half-life by route of exposure |
6.4 Metabolism |
6.5 Elimination by route of exposure |
7. TOXICOLOGY/TOXINOLOGY/PHARMACOLOGY |
7.1 Mode of action |
7.2 Toxicity |
7.2.1 Human data |
7.2.1.1 Adults |
7.2.1.2 Children |
7.2.2 Animal data |
7.2.3 Relevant in vitro data |
7.3 Carcinogenicity |
7.4 Teratogenicity |
7.5 Mutagenicity |
7.6 Interactions |
8. TOXICOLOGICAL/TOXINOLOGICAL ANALYSES AND BIOMEDICAL INVESTIGATIONS |
8.1 Material sampling plan |
8.1.1 Sampling and specimen collection |
8.1.1.1 Toxicological analyses |
8.1.1.2 Biomedical analyses |
8.1.1.3 Arterial blood gas analysis |
8.1.1.4 Haematological analyses |
8.1.1.5 Other (unspecified) analyses |
8.1.2 Storage of laboratory samples and specimens |
8.1.2.1 Toxicological analyses |
8.1.2.2 Biomedical analyses |
8.1.2.3 Arterial blood gas analysis |
8.1.2.4 Haematological analyses |
8.1.2.5 Other (unspecified) analyses |
8.1.3 Transport of laboratory samples and specimens |
8.1.3.1 Toxicological analyses |
8.1.3.2 Biomedical analyses |
8.1.3.3 Arterial blood gas analysis |
8.1.3.4 Haematological analyses |
8.1.3.5 Other (unspecified) analyses |
8.2 Toxicological Analyses and Their Interpretation |
8.2.1 Tests on toxic ingredient(s) of material |
8.2.1.1 Simple Qualitative Test(s) |
8.2.1.2 Advanced Qualitative Confirmation Test(s) |
8.2.1.3 Simple Quantitative Method(s) |
8.2.1.4 Advanced Quantitative Method(s) |
8.2.2 Tests for biological specimens |
8.2.2.1 Simple Qualitative Test(s) |
8.2.2.2 Advanced Qualitative Confirmation Test(s) |
8.2.2.3 Simple Quantitative Method(s) |
8.2.2.4 Advanced Quantitative Method(s) |
8.2.2.5 Other Dedicated Method(s) |
8.2.3 Interpretation of toxicological analyses |
8.3 Biomedical investigations and their interpretation |
8.3.1 Biochemical analysis |
8.3.1.1 Blood, plasma or serum |
8.3.1.2 Urine |
8.3.1.3 Other fluids |
8.3.2 Arterial blood gas analyses |
8.3.3 Haematological analyses |
8.3.4 Interpretation of biomedical investigations |
8.4 Other biomedical (diagnostic) investigations and their interpretation |
8.5 Overall Interpretation of all toxicological analyses and toxicological investigations |
8.6 References |
9. CLINICAL EFFECTS |
9.1 Acute poisoning |
9.1.1 Ingestion |
9.1.2 Inhalation |
9.1.3 Skin exposure |
9.1.4 Eye contact |
9.1.5 Parenteral exposure |
9.1.6 Other |
9.2 Chronic poisoning |
9.2.1 Ingestion |
9.2.2 Inhalation |
9.2.3 Skin exposure |
9.2.4 Eye contact |
9.2.5 Parenteral exposure |
9.2.6 Other |
9.3 Course, prognosis, cause of death |
9.4 Systematic description of clinical effects |
9.4.1 Cardiovascular |
9.4.2 Respiratory |
9.4.3 Neurological |
9.4.3.1 CNS |
9.4.3.2 Peripheral nervous system |
9.4.3.3 Autonomic nervous system |
9.4.3.4 Skeletal and smooth muscle |
9.4.4 Gastrointestinal |
9.4.5 Hepatic |
9.4.6 Urinary |
9.4.6.1 Renal |
9.4.6.2 Others |
9.4.7 Endocrine and reproductive systems |
9.4.8 Dermatological |
9.4.9 Eye, ears, nose, throat: local effects |
9.4.10 Haematological |
9.4.11 Immunological |
9.4.12 Metabolic |
9.4.12.1 Acid base disturbances |
9.4.12.2 Fluid and electrolyte disturbances |
9.4.12.3 Others |
9.4.13 Allergic reactions |
9.4.14 Other clinical effects |
9.4.15 Special risks |
9.5 Others |
9.6 Summary |
10. MANAGEMENT |
10.1 General principles |
10.2 Relevant laboratory analyses and other investigations |
10.2.1 Sample collection |
10.2.2 Biomedical analysis |
10.2.3 Toxicological/toxinological analysis |
10.2.4 Other investigations |
10.3 Life supportive procedures and symptomatic treatment |
10.4 Decontamination |
10.5 Elimination |
10.6 Antidote/antitoxin treatment |
10.6.1 Adults |
10.6.2 Children |
10.7 Management discussion |
11. ILLUSTRATIVE CASES |
11.1 Case reports from literature |
11.2 Internally extracted data on cases |
11.3 Internal cases |
12. ADDITIONAL INFORMATION |
12.1 Availability of antidotes/antitoxins |
12.2 Specific preventive measures |
12.3 Other |
13. REFERENCES |
13.1 Clinical and toxicological |
13.2 Botanical |
14. AUTHOR(S), REVIEWER(S), DATE(S) (INCLUDING UPDATES), COMPLETE ADDRESS(ES) |
POISONOUS PLANTS
1. NAME
1.1 Scientific name
Wisteria sinensis (Sims) Sweet Wisteria floribunda (Willd) DC
1.2 Family
Leguminosae (Fabaceae)
1.3 Common name(s)
Chinese Kidney Bean (UK)
Chinese Wisteria (UK) (W. sinensis)
Glicina (Uruguay, Spain)
Japanese Wisteria (UK) (W. floribunda)
Kidney Bean Tree (USA)
Wistaria (USA)
Wisteria (USA)
2. SUMMARY
2.1 Main risks and target organs
Hypovolemic shock because of fluid loss. Target organ is the
gastrointestinal tract.
2.2 Summary of clinical effects
Nausea, vomiting and abdominal pain. Diarrhoea is uncommon.
2.3 Diagnosis
Clinical features: mainly gastrointestinal.
Pharmacological diagnosis: not relevant.
Laboratory analysis: specimen of the plant for botanical
identification; samples for electrolytes.
2.4 First-aid measures and management principles
In asymptomatic patients decontamination measures should be
performed. In case of symptomatic patients fluid replacement
should be instituted if indicated. Antiemetics can be
useful.
2.5 Poisonous parts
All parts of the plant are toxic.
2.6 Main toxins
An uncharacterized glycoside, wisterine and a lectin.
3. CHARACTERISTICS
3.1 Description of the plant
3.1.1 Special identification features
Wisteria is a woody liane that can reach a height of 20
m, characterized by pendent racemes of light blue-
violet, sweetpea-like, scented flowers. It flowers in
springtime, and often again in the late summer. There
are varieties of pink and white flowers. The fruit are
pods (oblong and velvety) that persist through winter.
The leaves are alternates, caducae, imparipinnate.
Leaflets are lanceolate, and petiolate, with between 11
and 19 leaflets about 3-4 cm in length (Bianchini,
1981; Lampe, 1985; Frohne, 1983).
3.1.2 Habitat
Usually cultivated as ornamental covering walls,
balconies and bowers. Native to China, Japan and
Southern USA.
3.1.3 Distribution
Originally from China and Japan, Wisteria was brought
into Europe in 1816 (Bianchini, 1981). Wisterias are
hardy in the north but are most common in the south-
eastern USA, as far west as Texas (Lampe, 1985). It is
widely cultivated in temperate Europe.
3.2 Poisonous parts of the plant
All parts of this plant are toxic. Statements in the
literature that the flowers are nontoxic are in error (Lampe,
1985).
3.3 The toxin(s)
3.3.1 Name(s)
Wisterine; and an undefined lectin.
3.3.2 Description, chemical structure, stability
An uncharacterized glycoside, wisterine. The plant also
contains lectins, whose structures and haemagglutinating or
mitogenic effects have recently been studied (Frhone-Pfander,
1983; Lampe, 1985).
3.3.3 Other physico-chemical characteristics
No data available.
3.4 Other chemical contents of the plant
No data available.
4. USES/CIRCUMSTANCES OF POISONING
4.1 Uses
4.1.1 Uses
4.1.2 Description
Cultivated as ornamental. There are no medicinal uses.
4.2 High risk circumstances
Children playing with parts of the plant.
4.3 High risk geographical areas
No data available.
5. ROUTES OF ENTRY
5.1 Oral
Accidental or suicidal ingestion of portions of the plant.
5.2 Inhalation
Not relevant.
5.3 Dermal
No data available.
5.4 Eye
No data available.
5.5 Parenteral
No data available.
5.6 Others
No data available.
6. KINETICS
6.1 Absorption by route of exposure
No data available.
6.2 Distribution by route of exposure
No data available.
6.3 Biological half-life by route of exposure
No data available.
6.4 Metabolism
No data available.
6.5 Elimination by route of exposure
No data available.
7. TOXICOLOGY/TOXINOLOGY/PHARMACOLOGY
7.1 Mode of action
No data available.
7.2 Toxicity
7.2.1 Human data
7.2.1.1 Adults
No data available.
7.2.1.2 Children
It has been reported that two seeds are enough
to cause a severe intoxication in a child
(Faravel-Carrigues, 1978).
7.2.2 Animal data
No data available.
7.2.3 Relevant in vitro data
No data available.
7.3 Carcinogenicity
No data available.
7.4 Teratogenicity
No data available.
7.5 Mutagenicity
No data available.
7.6 Interactions
No data available.
8. TOXICOLOGICAL/TOXINOLOGICAL ANALYSES AND BIOMEDICAL INVESTIGATIONS
8.1 Material sampling plan
8.1.1 Sampling and specimen collection
8.1.1.1 Toxicological analyses
8.1.1.2 Biomedical analyses
8.1.1.3 Arterial blood gas analysis
8.1.1.4 Haematological analyses
8.1.1.5 Other (unspecified) analyses
8.1.2 Storage of laboratory samples and specimens
8.1.2.1 Toxicological analyses
8.1.2.2 Biomedical analyses
8.1.2.3 Arterial blood gas analysis
8.1.2.4 Haematological analyses
8.1.2.5 Other (unspecified) analyses
8.1.3 Transport of laboratory samples and specimens
8.1.3.1 Toxicological analyses
8.1.3.2 Biomedical analyses
8.1.3.3 Arterial blood gas analysis
8.1.3.4 Haematological analyses
8.1.3.5 Other (unspecified) analyses
8.2 Toxicological Analyses and Their Interpretation
8.2.1 Tests on toxic ingredient(s) of material
8.2.1.1 Simple Qualitative Test(s)
8.2.1.2 Advanced Qualitative Confirmation Test(s)
8.2.1.3 Simple Quantitative Method(s)
8.2.1.4 Advanced Quantitative Method(s)
8.2.2 Tests for biological specimens
8.2.2.1 Simple Qualitative Test(s)
8.2.2.2 Advanced Qualitative Confirmation Test(s)
8.2.2.3 Simple Quantitative Method(s)
8.2.2.4 Advanced Quantitative Method(s)
8.2.2.5 Other Dedicated Method(s)
8.2.3 Interpretation of toxicological analyses
8.3 Biomedical investigations and their interpretation
8.3.1 Biochemical analysis
8.3.1.1 Blood, plasma or serum
8.3.1.2 Urine
8.3.1.3 Other fluids
8.3.2 Arterial blood gas analyses
Acid-base balance.
8.3.3 Haematological analyses
Full blood count.
8.3.4 Interpretation of biomedical investigations
8.4 Other biomedical (diagnostic) investigations and their
interpretation
Hyponatremia, hypokalemia and hemoconcentration can be found.
8.5 Overall Interpretation of all toxicological analyses and
toxicological investigations
8.6 References
9. CLINICAL EFFECTS
9.1 Acute poisoning
9.1.1 Ingestion
Poisoning usually occurs after ingestion of seeds or
other parts of the plants. Symptoms can appear up to
24 hours after ingestion and include nausea, abdominal
pain and repeated vomiting.
Diarrhea is mild or absent; vomiting is sometimes bloody
or bilious (Hardin-Arena, 1974; Pronczuk & Laborde,
1988; Dreisbach, 1987). Ingestion of massive amounts
(from chewing the bark) have been associated with fluid
loss sufficient to cause hypovolemic shock (Lampe,
1985).
9.1.2 Inhalation
Not relevant.
9.1.3 Skin exposure
No data available.
9.1.4 Eye contact
No data available.
9.1.5 Parenteral exposure
No data available.
9.1.6 Other
No data available.
9.2 Chronic poisoning
9.2.1 Ingestion
No data available.
9.2.2 Inhalation
No data available.
9.2.3 Skin exposure
No data available.
9.2.4 Eye contact
No data available.
9.2.5 Parenteral exposure
No data available.
9.2.6 Other
No data available.
9.3 Course, prognosis, cause of death
In severe poisoning, the acute effects are followed by
hemodynamic and electrolyte disturbances (Hardin-Arena,
1974). Ingestion of massive amounts (from chewing the bark)
have been associated with fluid loss sufficient to cause
hypovolemic shock (Lampe, 1985). Death is due to hypovolemic
shock.
9.4 Systematic description of clinical effects
9.4.1 Cardiovascular
In acute poisoning, hypotension may precede hemodynamic
shock. Severe gastroenteritis may contribute to fluid
and electrolyte losses and therefore to the
cardiovascular effects.
9.4.2 Respiratory
No data available.
9.4.3 Neurological
9.4.3.1 CNS
No data available.
9.4.3.2 Peripheral nervous system
No data available.
9.4.3.3 Autonomic nervous system
No data available.
9.4.3.4 Skeletal and smooth muscle
No data available.
9.4.4 Gastrointestinal
Usually transient but intense abdominal pain, nausea and
vomiting which may be bloody or bilious vomiting. Usually
they are transitory (Pronczuk & Laborde, 1988).
Diarrhoea sometimes occurs.
9.4.5 Hepatic
No data available.
9.4.6 Urinary
9.4.6.1 Renal
No data available.
9.4.6.2 Others
No data available.
9.4.7 Endocrine and reproductive systems
No data available.
9.4.8 Dermatological
No data available.
9.4.9 Eye, ears, nose, throat: local effects
No data available.
9.4.10 Haematological
No data available.
9.4.11 Immunological
No data available.
9.4.12 Metabolic
9.4.12.1 Acid base disturbances
Metabolic alkalosis may occur.
9.4.12.2 Fluid and electrolyte disturbances
Because of the gastrointestinal loss of fluids
and electrolytes, hypokalemia or hyponatremia
may occur.
9.4.12.3 Others
No data available.
9.4.13 Allergic reactions
No data available.
9.4.14 Other clinical effects
No data available.
9.4.15 Special risks
No data available.
9.5 Others
No data available.
9.6 Summary
10. MANAGEMENT
10.1 General principles
In symptomatic patients, the aim of treatment is to maintain
fluid and electrolyte balance. Antiemetic treatment is
useful. Fluid replacement may be indicated (Lampe, 1985).
If the patient is asymptomatic, decontamination measures are
indicated with gastric lavage or emesis, followed by
activated charcoal (Dreisbach, 1987). Patients usually
become asymptomatic within 24 hours (Lampe, 1985).
10.2 Relevant laboratory analyses and other investigations
10.2.1 Sample collection
Specimen of the plant for botanical identification.
Blood samples for biomedical analyses (see section
8.3.1).
10.2.2 Biomedical analysis
Electrolytes, full blood count and acid-base balance
if necessary.
10.2.3 Toxicological/toxinological analysis
No data available.
10.2.4 Other investigations
No data available.
10.3 Life supportive procedures and symptomatic treatment
Fluid replacement and antiemetics if necessary.
10.4 Decontamination
Empty the stomach by inducing vomiting or performing gastric
lavage if the patient's clinical condition allows it and if
timing is appropriate. Give activated charcoal.
10.5 Elimination
No specific elimination procedures are indicated.
10.6 Antidote/antitoxin treatment
10.6.1 Adults
None
10.6.2 Children
None
10.7 Management discussion
11. ILLUSTRATIVE CASES
11.1 Case reports from literature
No data available
11.2 Internally extracted data on cases
One incident has been reported by the Poison Control Centre
of Montevideo (Hospital de Clinicas, Uruguay, 1988). Four
children between five and ten years old were playing with
the plant and ate an unknown number of seeds.
They were admitted and remained asymptomatic for 20 hours.
They then developed abdominal pain and vomiting, and two
became dehydrated. Treatment was based on fluid
replacement and recovery was complete (Pronczuk & Laborde,
1988).
11.3 Internal cases
12. ADDITIONAL INFORMATION
12.1 Availability of antidotes/antitoxins
No data available.
12.2 Specific preventive measures
Take special care of children playing near this plant.
12.3 Other
No data available.
13. REFERENCES
13.1 Clinical and toxicological
Dreisbach RH & Robertson WO (1987) Handbook of poisoning.
12th ed. Appleton-Lange. Norwalk, Connecticut.
Faravel-Carrigues JC, Castaig Y, et al. (1978) Bordeaux Med. 28.
Frohne D & Pfander H (1984) Poisonous Plants Ed. Wolfe.
Hardin JW & Arena JM (1974) Human poisoning from native and
cultivated plants. Duke University Press, 2nd ed. Kingsport,
Tennessee.
Lampe KF & McCann MA (1985) AMA Handbook of Poisonous and
Injurious Plants, AMA Chicago Illinois.
Pronczuk J & Laborde A (1988) Plantas Silvestres y de
Cultivo.
13.2 Botanical
Bianchini F & Carrara Pantano A (1981) Guía de Plantas y
Flores, Ed. Grijalbo 5° ed. pg. 184.
14. AUTHOR(S), REVIEWER(S), DATE(S) (INCLUDING UPDATES), COMPLETE
ADDRESS(ES)
Author: Dr J. Mallet
CIAT
Hospital de Clinicas - Piso 7
Av. Italia s/n
Montevideo
Uruguay
Tel: 598-2-470300
Fax: 598-2-470300
Date: June, 1991
Peer review: Singapore, November 1991
(Members: K. Hartigan-Go, A. Laborde, C. Leon,
L. Matainaho, W. Temple)
Update peer review: London, United Kingdom, February 1994
(Members: C. Alonzo, A. Furtado Rahde,
O. Kasilo, Z. Petrochenko, J. Trestrail,
N. Maramba, J. Szajewski, E. Wickstrom,
X. Zhang)